Gilenya Approved for Relapsing MS
Links shared publicly online about this topic.
- 854total visits
Gilenya Approved for Relapsing MS
View full resource at everydayhealth.com
Tags: Drug, Disability, FDA
Most Recently Shared on September 23, 2010 at 12:30 am By:
New drug approved by #FDA for relapsing MS http://ow.ly/2IkkJ #multiplesclerosis
Multiple Sclerosis: World-first pill for MS to be offered to thousands of British patients | Mail Online
dailymail.co.uk — “The NHS rationing body has approved the drug fingolimod which can halve relapses among sufferers compared with standard treatments.” View full resource at dailymail.co.uk
Most Recently Shared on March 17, 2012 at 12:56 pm By:
Multiple Sclerosis: World-first pill for MS to be offered to thousands of British patients: The NHS rationing bo... http://t.co/deH3thL6
Multiple Sclerosis: World-first pill for MS to be offered to thousands of British patients - QualityPoint Technologies
qualitypointtech.net — “The NHS rationing body has approved the drug fingolimod which can halve relapses among sufferers compared with standard treatments. (Source: the Mail online | Health)” View full resource at qualitypointtech.net
Most Recently Shared on March 17, 2012 at 12:00 pm By:
Multiple Sclerosis: World-first pill for MS to be offered to thousands of British patients: The NHS rationing body... http://t.co/iHvUwA2D
Oral MS Drug's Positive Result Buoys Biogen - WSJ.com
online.wsj.com — “The biotechnology company plans to seek regulatory approval early next year for its experimental pill, BG-12, after a clinical trial showed that patients had fewer MS relapses.” View full resource at online.wsj.com
Most Recently Shared on October 26, 2011 at 7:56 pm By:
Scott Strumello Patient Expert
http://t.co/Ld8D5lbR: Oral MS Drug's Positive Result Buoys Biogen http://t.co/4wUhsjan
PharmaLive: FDA approves supplemental new drug application for Novartis therapy Gilenya to include data showing reduction in T1 lesions in MS, a marker of disease activity
pharmalive.com — “PharmaLive: FDA approves supplemental new drug application for Novartis therapy Gilenya to include data showing reduction in T1 lesions in MS, a marker of disease activity” View full resource at pharmalive.com
Most Recently Shared on August 3, 2011 at 12:04 am By:
Novartis MS drug Gilenya gets new label info: Data on reduced T1 lesions, a marker for disease activity. http://bit.ly/q43Gfm
Biogen Idec Receives Approval In The European Union For AVONEX(R) PEN™
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) announced today that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a sing” View full resource at medicalnewstoday.com
Most Recently Shared on June 7, 2011 at 12:06 pm By:
Biogen Idec Receives Approval In The European Union For AVONEX(R) PEN™ http://mnt.to/3WRt #multiplesclerosis
First Oral Treatment For Highly Active Relapsing Remitting Multiple Sclerosis Provides New Choice For UK Patients Failing On Injections
medicalnewstoday.com — “The first oral treatment for multiple sclerosis (MS) has been given the green light by UK regulators and is now available in the UK. Fingolimod0.5 mg (Gilenya™) has been authorised for peopl” View full resource at medicalnewstoday.com
Most Recently Shared on April 19, 2011 at 2:59 pm By:
First Oral Treatment For Highly Active Relapsing Remitting Multiple Sclerosis Provides New Choice For UK Patient... http://bit.ly/gBGjj9
Novartis Receives European Commission Approval For Gilenya(R), The First Oral Multiple Sclerosis Treatment For Use In The EU
medicalnewstoday.com — “The European Commission has granted Novartis approval for Gilenya® (fingolimod) 0.5 mg daily as a disease modifying therapy in patients with highly active relapsing-remitting multiple sclerosi” View full resource at medicalnewstoday.com
Most Recently Shared on March 22, 2011 at 12:06 pm By:
Novartis Receives European Commission Approval For Gilenya(R), The First Oral Multiple Sclerosis Treatment For U... http://bit.ly/frRVEL
Novartis Receives European Commission Approval For Gilenya(R), The First Oral Multiple Sclerosis Treatment For Use In The EU
medicalnewstoday.com — “The European Commission has granted Novartis approval for Gilenya® (fingolimod) 0.5 mg daily as a disease modifying therapy in patients with highly active relapsing-remitting multiple sclerosi” View full resource at medicalnewstoday.com
Most Recently Shared on March 22, 2011 at 7:05 am By:
Novartis Receives European Commission Approval For Gilenya(R), The First Oral Multiple Sclerosis Treatment For Use In ... http://mnt.to/3SwC
Multiple Sclerosis Oral Treatment Approved in Canada
disabled-world.com — “Gilenya (fingolimod) is the first disease modifying oral therapy developed for the relapsing-remitting form of multiple sclerosis (MS)” View full resource at disabled-world.com
Most Recently Shared on March 10, 2011 at 2:50 pm By:
Disabled World Health Advocate and Health News
Multiple Sclerosis Oral Treatment Approved in Canada http://ff.im/-zovzM
Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging
physorg.com — “(PhysOrg.com) -- A first-line treatment for relapsing forms of multiple sclerosis (MS) was approved in September 2010 by the US Food and Drug Administration: FTY720 (fingolimod, Gilenya), which acts as a sphingosine 1-phosphate (S1P) receptor modulator.” View full resource at physorg.com
Most Recently Shared on February 4, 2011 at 7:03 pm By:
Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging: (PhysOrg.com) -- ... http://bit.ly/ecouE5
An ITG Majestic Market Research Study Indicates A Bright Future For Gilenya, Despite Concerns About Its Safety
medicalnewstoday.com — “A study published this week by ITG (NYSE: ITG) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and” View full resource at medicalnewstoday.com
Most Recently Shared on December 21, 2010 at 1:05 pm By:
An ITG Majestic Market Research Study Indicates A Bright Future For Gilenya, Despite Concerns About Its Safety http://mnt.to/3Pj9
Gilenya offers more benefits for MS therapy than previously realized
news-medical.net — “In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent t” View full resource at news-medical.net
Most Recently Shared on December 21, 2010 at 11:29 am By:
Gilenya offers more benefits for MS therapy than previously realized: In September, patients suffering from mult... http://bit.ly/hnV5Vj
Novartis' Gilenya uptake to increase
news-medical.net — “A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.” View full resource at news-medical.net
Most Recently Shared on December 20, 2010 at 10:50 am By:
Novartis' Gilenya uptake to increase: A study published this week by ITG revealed that Novartis recently approve... http://bit.ly/i48uE6
GILENYA - New Product Releases - MPR
empr.com — “For relapsing forms of multiple sclerosis (MS): to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.” View full resource at empr.com
Most Recently Shared on October 22, 2010 at 1:51 pm By:
MPR News: GILENYA: Fingolimod (as HCl) 0.5mg; caps. http://bit.ly/bNguTv
Physicians anticipate new oral therapies for multiple sclerosis patients
news-medical.net — “Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.” View full resource at news-medical.net
Most Recently Shared on October 13, 2010 at 12:50 pm By:
Physicians anticipate new oral therapies for multiple sclerosis patients: Physicians are anticipating the arrival ... http://bit.ly/bQogNC
Advertisement
